Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Financings

Corvus Pharmaceuticals, Inc.

Financings

RaiseDate
Public offering of common stock
Closed: US$201.2M raised · US$22.15 a share · Jefferies +3
Dealers: Jefferies (co-lead), Goldman Sachs & Co. LLC (co-lead), Mizuho, Ladenburg Thalmann
Use of proceeds: Working capital and general corporate purposes, including R&D for Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma trials
Jan 23, 2026
Warrant exercise of common stock warrants
Closed: US$31.3M raised · US$3.5 a share
Buyers: Richard Miller (559,073 shares purchased for $1,956,756)
Insiders: CEO Richard Miller purchased 559,073 shares for $1,956,756 through early exercise of warrants
May 8, 2025
Warrant exercise of common stock warrants
Announced: about US$12.7M
Buyers: Samlyn Capital (exercising warrants to purchase 3,633,978 shares of common stock)
Dec 18, 2024

Read by 6ix AI from the company's releases